In this online CME self-learning program:
In the United States, over 98 million adults have a dyslipidemia, which are defined by a total cholesterol levels above 200mg/dL and, more importantly, nearly a third of the U.S. population has elevated levels of low-density lipoprotein cholesterol (LDL-C). These epidemiological findings have concerned healthcare professionals and public health policy stakeholders alike for decades, given that plasma lipoprotein abnormalities predispose individuals to cerebro- and peripheral vascular arterial disease and constitute one of the major known risk factors for coronary heart disease. As recently as 2014, less than half of adults with high LDL-C were receiving treatment to lower their levels, constituting a major practice gap. Some progress has been made in recent years: the treatment of high LDL-C among Americans has increased from only 28.4% in 1999-2002 to 48.1% in 2005-2008. Even so, millions remain untreated.
Faculty member introduction, disclosures
Major findings from AHA 2016 , including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice (specific content contingent upon conference content)
Predicted of applicability to clinical practice and patient cases, where relevant
The following healthcare professionals: cardiology and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in cardiology; and any other clinicians with an interest in dyslipidemia and ASCVD.
This program is supported by an educational grant from AMGEN.
Release Date: February 08, 2017 -- Expiration Date: February 08, 2019
Faculty: Matthew Budoff, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Budoff, MD has received financial compensation from AMGEN and Sanofi/Regeneron for speakers bureau and/or research
Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.